Navigation Links
Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
Date:10/26/2008

- Ninety-six week ARTEMIS data presented at ICAAC -

BRIDGEWATER, N.J., Oct. 26 /PRNewswire/ -- Ninety-six week results presented today from a phase 3, randomized, open-label, ongoing clinical trial showed that 79 percent of treatment-naive HIV-1 infected adults taking PREZISTA(R) 800 mg (two 400 mg tablets) with 100 mg ritonavir (r) once daily reached an undetectable viral load (<50 copies/mL) at week 96, compared with 71 percent of patients taking lopinavir/ritonavir 800 mg/200 mg once daily (or 400 mg/100 mg twice daily), each with a fixed dose of emtricitabine and tenofovir disoproxil fumarate.

Results from the study, known as ARTEMIS, were presented today at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC. ARTEMIS is a 192-week study comparing the efficacy and safety of the protease inhibitors (PIs) PREZISTA/r and lopinavir/r in treatment-naive adults with HIV (those who have never taken HIV medication before). PREZISTA was developed by Tibotec Pharmaceuticals and is marketed in the U.S. by Tibotec Therapeutics, a division of Ortho Biotech Products, L.P.

At 48 weeks, the primary objective of ARTEMIS was reached when PREZISTA/r was demonstrated to be non-inferior to lopinavir/r for virologic response (confirmed HIV RNA < 50 copies/mL). The difference between the treatment arms was not significant at week 48. The pre-planned safety and efficacy analysis at 96 weeks was a secondary endpoint. At 96 weeks, the study showed PREZISTA/r was non-inferior to lopinavir/r for virologic response. The estimated difference in virologic response between the treatment groups was eight percent and was statistically significant (95 percent confidence interval 1.8; 14.7). The 96-week results from ARTEMIS will be submitted to the FDA.

"This study offers the healthcare provider community long-term efficacy and safety data for PREZISTA in treatment-naive adult patients," said Tony Mills, M.D., ART
'/>"/>

SOURCE Tibotec Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... On Tuesday, July 1, 2014, ... the 116 th Judicial District Court in ... RegenLab USA, LLC ("Defendant") for Tortious ... through false and misleading actions, fraud, fraud-in-the-inducement, business ... through libel, disparagement, defamation, misrepresentation, and violating the ...
(Date:7/23/2014)... Creekridge Capital, an independent vendor-focused finance ... so far in 2014 to their portfolio of ... from both the healthcare and technology industries. They ... multi-national companies. Each of these new vendors take ... including: standard leasing products, subscription solutions, a dedicated ...
(Date:7/23/2014)...  Mezzion Pharma Co. Ltd., announced that it has ... udenafil to treat adolescents who have undergone the Fontan ... program will follow protocols developed by a subcommittee made ... a multi-center clinical research network funded by the National ... Institutes of Health (NIH). The studies, ...
Breaking Medicine Technology:Creekridge Capital Signs Several New Vendor Partners 2Mezzion Pharma Initiates Clinical Development Program To Evaluate Udenafil In Adolescents With Single Ventricle Heart Defects 2
... (Nasdaq: BMRN ) today hosted a Research ... team and industry experts provided an update on BioMarin,s ... pipeline. "We believe 2011 has been a ... and early stage clinical development programs," said Jean-Jacques Bienaime, ...
... Modern Materials Division of Heraeus Kulzer, LLC, the ... The division has been the leader in the U.S. dental ... Modern Materials was founded in 1946 in St. Louis, ... chemist, was "Mr. Inside" while Mr. Piper, the consummate salesman, ...
Cached Medicine Technology:Highlights from BioMarin's Research & Development Day 2Highlights from BioMarin's Research & Development Day 3Highlights from BioMarin's Research & Development Day 4Highlights from BioMarin's Research & Development Day 5Highlights from BioMarin's Research & Development Day 6Heraeus' Modern Materials Division Celebrates 65th Anniversary 2Heraeus' Modern Materials Division Celebrates 65th Anniversary 3
(Date:7/23/2014)... Steven Reinberg HealthDay Reporter ... Many obese and overweight American children and teens look ... fine, U.S. health officials reported Wednesday. "Being overweight ... as high blood pressure, high cholesterol and diabetes," said ... U.S. Centers for Disease Control and Prevention,s National Center ...
(Date:7/23/2014)... The next episode of “Extreme Weight Loss” ... was physically fit through childhood and adolescence. After becoming ... heart-wrenching decision to give her son up for adoption. ... years, and she punished herself by overeating, gaining nearly ... non-competitive approach to weight loss transformations, “Extreme Weight Loss” ...
(Date:7/23/2014)... 23, 2014 Home Care Assistance ... for seniors, is proud to announce the next installment ... in a wide range of health and wellness-related fields. ... and award-winning author Nancy Kriseman, and will cover the ... prevent burnout by becoming more self-aware. In particular, Nancy ...
(Date:7/23/2014)... Painful or itchy skin lesions could be a warning ... have multiple lesions that are suspicious looking, and those ... for non-melanoma skin cancers," study author Dr. Gil Yosipovitch, ... said in a Temple University Health System news release. ... patients who were confirmed to have skin cancer lesions ...
(Date:7/23/2014)... supports a growing body of research suggesting a ... in treating postmenopausal breast cancer, with fewer detrimental ... standard anti-hormone therapies. The study will be published ... Reproductive Biology and Endocrinology . , Breast ... women in the United States. Approximately 70% of ...
Breaking Medicine News(10 mins):Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:“Extreme Weight Loss”: Cassie’s journey begins at the University of Colorado Anschutz Health and Wellness Center 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Painful, Itchy Patches Could Be Sign of Skin Cancer 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5
... Amanda Gardner HealthDay Reporter , FRIDAY, Dec. 16 ... who receive targeted radiation to the breast after a lumpectomy ... only about a third of these women were considered "suitable" ... study published in the Dec. 16 online issue of the ...
... SAGE and the European Society of Cardiology (ESC) ... Journal: Acute Cardiovascular Care. The first issue will be ... represents over 70,000 cardiology professionals across Europe and the ... including publishing seven of the world,s leading cardiology journals. ...
... 17 (HealthDay News) -- The busy holiday season may disrupt ... it is especially important to remember to look after your ... people to consume sugary treats and drink alcoholic beverages more ... General Dentistry, said in an academy news release. "Additionally, ...
... Will a drug used to treat childhood acute lymphoblastic leukemia ... UB associate professor of pharmaceutical sciences, Javier G. ... research and clinical practice, has focused recent efforts on trying ... study in the Journal of Clinical Oncology looked for the ...
... Scientists may have a way to double the efficacy ... Sciences University scientists have devised a way to reduce lung ... caused by radiation therapy., "Radiation is a great therapy ... Dynan, biochemist and Associate Director of Research and Chief, Nanomedicine ...
... FRIDAY, Dec. 16 (HealthDay News) -- Chronic pain can ... the affected partner,s ability to cope with the pain, ... shown that validation of a spouse,s emotions (showing respect ... invalidation of emotions (showing hostility or no interest) increases ...
Cached Medicine News:Health News:Targeted Radiation for Breast Cancer May Be Overused: Study 2Health News:Targeted Radiation for Breast Cancer May Be Overused: Study 3Health News:Sage and European Society of Cardiology extend publishing partnership 2Health News:Dentist Gives Advice to Keep Holiday Smiles Bright 2Health News:Childhood cancer drugs cure now, may cause problems later, UB research shows 2Health News:Scientists may be able to double efficacy of radiation therapy 2Health News:Spouse's Reaction May Affect Pain Management 2
Large image and wide-angle design....
Large-image field with titanium couplers for c-mount scopes. 30mm focal length....
High intensity lamp with built-in, switchable spare lamp. Low-noise fan with reduced air turbulence....
PDA application listing specific ICD-9 coding listed in new Medicare National Coverage Determinations....
Medicine Products: